Espervita Therapeutics
Biopharmaceutical company focused on discovery and preclinical development of metabolic reprogramming therapies. The organization is developing liver- and kidney-selective small-molecule inhibitors of acetyl-CoA metabolic enzymes and conducts in vivo and translational studies to advance candidates for metabolic liver disease, chronic kidney disease, fibrosis, and hepatocellular carcinoma. Leadership describes experience across drug discovery, preclinical strategy, regulatory planning, and product commercialization.
Industries
Nr. of Employees
small (1-50)
Espervita Therapeutics
Patents
Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease
US-12396972-B2
View DetailsFunctionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease
US-12252467-B2
View DetailsFunctionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease
US-12180151-B2
View DetailsFunctionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease
US-11737995-B2
View DetailsFunctionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease
US-11730712-B2
View DetailsFunctionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease
US-11267778-B2
View Details
Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease
US-12396972-B2
View DetailsFunctionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease
US-12252467-B2
View DetailsFunctionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease
US-12180151-B2
View DetailsFunctionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease
US-11737995-B2
View DetailsFunctionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease
US-11730712-B2
View DetailsFunctionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease
US-11267778-B2
View DetailsProducts
Preclinical liver- and kidney-selective acetyl-CoA enzyme inhibitor (lead candidate)
First-in-class, tissue-selective small-molecule inhibitor of acetyl-CoA metabolic enzymes in preclinical development. Demonstrated effects in preclinical models include metabolic benefit, reversal of liver fibrosis, preservation of kidney function, and reduction in tumor burden.
EVT0185
A first-in-class, liver- and kidney-selective inhibitor of acetyl-CoA metabolic enzymes that demonstrates broad efficacy in preclinical models—lowering blood glucose and lipid synthesis, reversing MASH and liver fibrosis, preserving kidney function, and decreasing HCC tumor burden.
Preclinical liver- and kidney-selective acetyl-CoA enzyme inhibitor (lead candidate)
First-in-class, tissue-selective small-molecule inhibitor of acetyl-CoA metabolic enzymes in preclinical development. Demonstrated effects in preclinical models include metabolic benefit, reversal of liver fibrosis, preservation of kidney function, and reduction in tumor burden.
EVT0185
A first-in-class, liver- and kidney-selective inhibitor of acetyl-CoA metabolic enzymes that demonstrates broad efficacy in preclinical models—lowering blood glucose and lipid synthesis, reversing MASH and liver fibrosis, preserving kidney function, and decreasing HCC tumor burden.
Services
Discovery and preclinical advancement of tissue-selective small-molecule inhibitors targeting metabolic enzymes.
Design and execution of disease-relevant in vivo models and translational studies to support IND-enabling data packages and publication.
Integrated regulatory planning encompassing IND/NDA strategy, CMC interface, and electronic submission workflows.
Program-level project management including document management, cross-functional coordination, and archive systems to support clinical development.
Operational expertise for commercial launch of molecular diagnostics and related commercialization planning.
Discovery and preclinical advancement of tissue-selective small-molecule inhibitors targeting metabolic enzymes.
Design and execution of disease-relevant in vivo models and translational studies to support IND-enabling data packages and publication.
Integrated regulatory planning encompassing IND/NDA strategy, CMC interface, and electronic submission workflows.
Program-level project management including document management, cross-functional coordination, and archive systems to support clinical development.
Operational expertise for commercial launch of molecular diagnostics and related commercialization planning.
Expertise Areas
- Metabolic disease drug discovery
- Preclinical development and translational research
- Regulatory strategy and submissions
- Project and program management for drug development
Key Technologies
- Acetyl-CoA metabolic enzyme inhibition
- Tissue-selective small-molecule targeting (liver and kidney)
- In vivo disease models (MASH, liver fibrosis, CKD, HCC)
- Translational validation aligning preclinical endpoints with clinical relevance
News & Updates
Press release describing preclinical results showing tumor reduction and immune activation in MASH-driven HCC models following treatment with the company's lead acetyl-CoA metabolic enzyme inhibitor.
Demonstration of reversal of metabolic dysfunction and liver fibrosis in Cell Metabolism publication
Press release announcing a Cell Metabolism publication reporting reversal of metabolic dysfunction and liver fibrosis in preclinical studies of the lead acetyl-CoA metabolic enzyme inhibitor.
Press release describing preclinical results showing tumor reduction and immune activation in MASH-driven HCC models following treatment with the company's lead acetyl-CoA metabolic enzyme inhibitor.
Demonstration of reversal of metabolic dysfunction and liver fibrosis in Cell Metabolism publication
Press release announcing a Cell Metabolism publication reporting reversal of metabolic dysfunction and liver fibrosis in preclinical studies of the lead acetyl-CoA metabolic enzyme inhibitor.